Drug Discovery Webinars
-
GLP And The Impact To Start Up Companies
4/18/2022
Good Laboratory Practice is often used in laboratories and is necessary for specific investigations. What does it mean? And how can it help start-up companies? Watch this video to learn more.
-
The NanoAssemblr® Spark™ Robust Low Volume RNA-Lipid Nanoparticle Formulation
4/14/2022
Develop RNA-lipid nanoparticles (LNPs) in under 10 seconds for drug discovery and early preclinical development. The NanoAssemblr®️ Spark™ instrument enables rapid µL formulations to conserve limited and expensive ingredients with minimal waste.
-
End-To-End Capacity With Flexibility, Infrastructure, And Expertise
1/25/2021
Whether rapidly scaling manufacturing capabilities, condensing supply chains, accelerating the availability of emerging therapies, or reducing the risk of a shortage, the pharmaceutical manufacturing platform can be the difference between success and failure for a biologic therapy.
-
Cell-Based Assays In A GMP Environment: Approaches For Clinical And Commercial Stability Studies
12/11/2018
This presentation demonstrates that in vitro, cell-based assays is an indispensable tool to quantify the biological activities, and to support the potency tests, for bio therapeutics.
-
Facility Overview Video: Scorpius BioManufacturing
Learn how a facility that includes characterization testing, bioassays, and QC located at the same site as GMP manufacturing can help you forge a faster path to clinic and product commercialization.
-
How Drug Delivery Is Enabling A Clinical Trial For Glioblastoma
Discover highly promising in-vivo data, enabled by a nanoformed drug product for the treatment of glioblastoma multiforme (GBM).
-
Integrating Early Development With Clinical Supply
In the era of seamless development, reducing time to the clinic and getting rapid approval is key. An integrated approach can accelerate timelines, avoid communication pitfalls, and improve outcomes.
-
Overcoming Formulation Challenges For mRNA, High-Concentration Proteins
Increased demand for protein delivery and the emergence of advanced modalities – including mRNA – are introducing new challenges to the development lifecycle, such as high-concentration formulations.
-
Nanoscale Technology's Potential: A Fireside Chat With Industry Leaders
Nanoform CEO Edward Haeggstrom and Shawn Davies, head of drug delivery, biopharmaceuticals development, AstraZeneca, discuss the potential of nanoscale medicines and delivery devices.
-
Formulation Technologies For Developing Dry Powders For Inhalation
Examine challenges and key considerations for spray-dried formulations for inhalation, along with a review of current technologies and approved products utilizing particle engineering approaches.